NDC 67296-2123-03 - Buprenorphine HCl
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 67296-2123
- Requested NDC
- 67296-2123-03
- Package NDCs from labels
- 67296-2123-3, 67296-2123-03
- Manufacturer
- Redpharm Drug
- Effective date
- 2025-12-23
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Buprenorphine HCl - Redpharm Drug | Redpharm Drug | 2025-12-23 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 67296-2123-3 | Buprenorphine HCl | 30 in 1 BOTTLE | TABLET | 30 | 4 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 67296-2123 | BUPRENORPHINE HCL TABLET [REDPHARM DRUG] | 1 | Current NDC, 1 package rows | 20250313_301eaed5-8499-ad95-e063-6294a90a58f5.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Clinical Solutions Wholesale, LLC | 8f2b94dc-f42f-45d5-8274-9e748ec20ef0 | 2026-03-05 | Warnings, Adverse reactions | 56W8MW3EN1 |
| buprenorphine hydrochloride | BUPRENORPHINE HYDROCHLORIDE | PAI Holdings, LLC dba PAI Pharma | 442831cf-9636-433a-9a12-e9a8cd31f72a | 2026-02-28 | Warnings, Adverse reactions | 351265 351264 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | PAI Holdings, LLC dba PAI Pharma | d5b011ef-f1be-47f2-8f8b-07553f36193c | 2026-02-28 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Kidnex IV | GINKGO BILOBA, ALPHA-KETOGLUTARICUM ACIDUM, CITRICUM ACIDUM, FUMARICUM ACIDUM, MALICUM ACIDUM, PYRUVIC ACID, SUCCINICUM ACIDUM, ARGENTUM METALLICUM, AURUM METALLICUM, CUPRUM METALLICUM, GERMANIUM SESQUIOXIDE, MERCURIUS VIVUS, NUX VOMICA, KIDNEY (SUIS), LYMPH NODE (SUIS), NAPHTHOCHINONUM, NATRUM OXALACETICUM, PHOSPHORUS, URINARY BLADDER (SUIS), ACONITICUM ACIDUM, CIS- | Energique, Inc. | 23de6b8e-7622-4ba6-89f7-37bd151687e2 | 2026-02-26 | Warnings | XF417D3PSL |
| Tricitrates | TRICITRATES | Chartwell Governmental & Specialty RX, LLC. | c4ff0407-3930-4c48-afd4-d2cb3e1b18f4 | 2026-02-25 | Warnings, Adverse reactions | 1Q73Q2JULR |
| Leader Extra Strength Effervescent Antacid and Pain Reliever | ASPIRIN, CITRIC ACID, SODIUM BICARBONATE | Cardinal Health | c5d7bf5f-3e59-52f2-e053-2a95a90a4a00 | 2026-02-25 | Warnings | XF417D3PSL |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Redpharm Drug | 300ae3d0-464c-d0be-e063-6294a90a7f9d | 2026-02-21 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Unit Dose Solutions, Inc. | 4b301ad7-ac0e-f849-e063-6394a90a27d5 | 2026-02-19 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Mitochondria Pro | ARALIA QUINQUEFOLIA, ARNICA MONTANA, ADENOSINUM TRIPHOSPHORICUM DINATRUM, ALPHA-KETOGLUTARICUM ACIDUM, ASCORBICUM ACIDUM, ALPHA-LIPOICUM ACIDUM, CALCAREA CARBONICA, CITRICUM ACIDUM, CUPRUM METALLICUM, CYSTEINUM, FERRUM METALLICUM, IODIUM, LEVOTHYROXINUM, MAGNESIUM GLUCONICUM DIHYDRICUM, MALICUM ACIDUM, MANGANUM ACETICUM, NADIDUM, NATRUM PYRUVICUM, NICOTINAMIDUM, PYRIDOXINUM HYDROCHLORICUM, RIBOFLAVINUM, SELENIUM METALLICUM, SULPHUR, THIAMINUM HYDROCHLORICUM, UBIDECARENONUM, ZINCUM METALLICUM, | Energique, Inc. | 2f365207-b730-428d-9465-8853e86e79ff | 2026-02-18 | Warnings | XF417D3PSL |
| Buprenorphine | BUPRENORPHINE | Sun Pharmaceutical Industries, Inc. | 9fd1f18f-0b0f-4059-b603-19ecbf0ed63a | 2026-02-11 | Warnings, Adverse reactions | 351265 351264 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Sun Pharmaceutical Industries, Inc. | 91b68606-05de-4586-ae31-07e8cc9160cf | 2026-02-10 | Warnings, Adverse reactions | 56W8MW3EN1 |
| GoodSense Eye Drops Advanced Relief Moisturizer | DEXTRAN, POLYETHYLENE GLYCOL 400, POVIDONE, TETRAHYDROZOLINE HCL | Sportpharm LLC | 8d58dcbb-72a0-41f0-9eeb-613072a6d7ae | 2026-02-06 | Warnings | FZ989GH94E |
| BUPRENORPHINE | BUPRENORPHINE | A-S Medication Solutions | bfb02ea5-22f2-432e-afc8-f1dbe2ea0614 | 2026-02-06 | Warnings, Adverse reactions | 351265 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Actavis Pharma, Inc. | 6cccf229-9611-4b6f-8f1b-acc8ff1ed3f8 | 2026-02-06 | Warnings, Adverse reactions | 56W8MW3EN1 |
| MINIDROPS | LUBRICANT EYE DROPS | Optics Laboratory, Inc | c13c5f91-50df-471c-a7c9-1747a2ac1250 | 2026-02-03 | Warnings | FZ989GH94E |
| Buprenorphine HCl and Naloxone HCl | BUPRENORPHINE AND NALOXONE | Amneal Pharmaceuticals LLC | 17b63f10-c9df-44be-80fa-6f1c305583b8 | 2026-02-02 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Camber Pharmaceuticals, Inc. | 221195e4-de08-414c-af08-a611a74789de | 2026-01-30 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Sodium Citrate and Citric Acid | SODIUM CITRATE AND CITRIC ACID MONOHYDRATE | Atlantic Biologicals Corp. | 42d837ae-2578-46df-92d2-24774964aaad | 2026-01-28 | Adverse reactions | 1Q73Q2JULR XF417D3PSL |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Camber Pharmaceuticals, Inc. | 5ab2d4e4-3c8c-413a-b147-23eafbde313a | 2026-01-28 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine | BUPRENORPHINE | Hikma Pharmaceuticals USA Inc. | 1bf8b35a-b769-465c-a2f8-099868dfcd2f | 2026-01-24 | Warnings, Adverse reactions | ANDA078633 0054-0176 351265 351264 e59c3c4f-a9cc-412b-b001-b9e430f537c5 1bf8b35a-b769-465c-a2f8-099868dfcd2f 56W8MW3EN1 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.